| Similar Articles |
|---|
 |
The Motley Fool
March 30, 2005
Stephen D. Simpson |
Clinical Trials Cost Biotechs More The failure of edifoligide means little to Bristol-Myers, but a great deal to Corgentech. In the grand scheme of things, there's not much new here -- the large, well-stocked pharmaceutical goes on its way, and the biotech stock gets pummeled.   |
The Motley Fool
November 29, 2004
Charly Travers |
Genta Is Worth Nada Latest trial failure leaves the pharmaceutical company with few options. Without Genasense, Genta is essentially a shell of a company with no means of creating value for shareholders. |
The Motley Fool
November 9, 2004
Charly Travers |
Genta's on the Ropes Aventis' exit leaves the pharmaceutical company in dire straits. Genta's stock opened down 40% this morning and is now down 85% for the year. |
The Motley Fool
February 17, 2004
David Nierengarten |
Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications. |
The Motley Fool
September 8, 2006
Ralph Casale |
Genta's Down, but Is It Out? An FDA advisory committee voted not to recommend Genta's lead drug, Genasense, for approval. The news has knocked Genta's stock down by nearly two-thirds over the past week. |
The Motley Fool
May 13, 2004
Charly Travers |
Avoiding Biotech Land Mines Successful biotech investing depends upon not getting caught up in bad situations. Lessons learned from these case studies can help us from getting trapped in similar situations in the future. |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
